微创玻璃体切除术治疗严重增生性糖尿病视网膜病变
本研究纳入48例(53眼)严重增生性糖尿病视网膜病变患者,采用术前玻璃体腔注射康柏西普联合27G+微创玻璃体切除术,术后最佳矫正视力显著提高,首次和末次视网膜复位率分别为92.5%和96.2%。术前视网膜激光光凝组各项参数优于无光凝组但差异无统计学意义。
要点
- 微创玻璃体切除术可显著改善严重PDR患者术后视力且安全性良好。
- 术后首次和末次随访视网膜复位率分别为92.5%和96.2%。
- 术前视网膜激光光凝可能有助于术后视力恢复但差异无统计学意义。
核心结论
- 最小量化玻璃体切除术能使严重PDR患者术后获得较好视功能,以较小创伤获取较大收益。
- 术前视网膜激光光凝可能有助于术后视力恢复。
研究设计与样本
- 系列病例研究及队列研究,纳入2017年1月1日至2019年3月30日天津医科大学眼科医院48例(53眼)严重PDR患者。
- 男性28例,女性20例,年龄53.5(40.0,59.0)岁。
- 所有患者术前3天玻璃体腔注射康柏西普,采用27G+玻璃体切除系统完成标准三通道玻璃体切除术。
- 按术前是否进行视网膜激光光凝分为光凝组和无光凝组分别分析。
- 采用t检验、秩和检验及χ²检验进行统计学分析。
主要发现
- 所有患者玻璃体腔注射康柏西普后均无严重不良反应发生。
- 术后BCVA较术前显著提高(χ²=125.11,P<0.01),logMAR BCVA从术前1.90(1.30,2.30)改善至术后1周1.00(0.70,1.90)、1个月0.80(0.50,1.30)、3个月0.70(0.40,1.20)、6个月0.70(0.40,1.20)。
- 术后首次和末次随访视网膜复位率分别为92.5%(50/53)和96.2%(51/53)。
- 2只眼术后发生持续1周及以上的异常眼压;5只眼(9.4%)复发玻璃体积血;4只眼(7.5%)发生视网膜脱离;未发生术后眼内炎、脉络膜脱离或切口相关视网膜裂孔。
- 光凝组术中(手术时间、硅油填充率、视网膜切开术率)及术后(术后BCVA、首次随访复位率、末次随访复位率、再手术率)参数与无光凝组相比差异无统计学意义(P>0.05),但光凝组具有更好的趋势。
关键数值与推荐
- 术后首次视网膜复位率92.5%(50/53),末次随访视网膜复位率96.2%(51/53)。
- 术后BCVA较术前显著提高(χ²=125.11,P<0.01)。
- 光凝组与无光凝组各项参数比较P>0.05。
临床怎么用
- 对严重PDR患者可采用术前玻璃体腔注射康柏西普联合27G+微创玻璃体切除术,以解除牵拉为主,不追求彻底清除增生机化膜。
- 术前视网膜激光光凝可能有助于术后视力恢复,但需进一步研究证实。
局限性
- 本研究为单中心系列病例研究及队列研究,样本量有限(48例53眼)。
- 光凝组与无光凝组差异无统计学意义,术前光凝的获益趋势需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To report the efficacy and safety of minimally invasive vitrectomy for the treatment of severe proliferative diabetic retinopathy (PDR) and the effect of preoperative retinal photocoagulation on prognosis. Methods: Case-series study and cohort study. This study included 48 severe PDR patients (53 eyes). There are 28 males and 20 females. The average age was 53.5 (range, 40.0 to 59.0) years old. Patients were divided into two groups according to whether preoperative retinal photocoagulation was performed. Under the guidance of the concept of minimally invasive vitrectomy, all patients received intravitreal injection of conbercept 3 days before standard pars plana vitrectomy with a 27G+ vitrectomy system. To relieve traction, the proliferative fibrovascular membrane was divided into islands as small as possible. It was not necessary to pursue a complete removal of the proliferative membrane. The 27G+ vitrector was flexibly applied as a multifunctional tool for membrane removal by reducing frequencies at which the device entered and left the eye. Intraocular retinal photocoagulation was performed in the main area. The primary outcome measures were best corrected visual acuity (BCVA) and retinal reattachment rate, and the secondary outcome measures were intraoperative and postoperative complications. Statistical analysis was performed using t test, rank sum test and χ² test. Results: All patients tolerated intravitreal conbercept, with no serious intraoperative or postoperative adverse events. Postoperative BCVA values were improved significantly compared with preoperative values (χ²=125.11, P<0.01). The mean logMAR BCVA improved from 1.90 (1.30, 2.30) preoperatively to 1.00 (0.70, 1.90) at 1 week postoperatively, 0.8 (0.5, 1.3) at 1 month postoperatively, 0.7 (0.40, 1.20) at 3 months postoperatively, and 0.70 (0.40, 1.20) at 6 months postoperatively. The visual function increased progressively with time. Postoperatively, the primary and final reattachment rates were 92.5% (50/53) and 96.2% (51/53), respectively. Abnormal intraocular pressure lasted for more than one week occurred in 2 eyes; Vitreous hemorrhage recurred in 5 eyes; Retinal detachment occurred in 4 eyes (7.5%); No postoperative endophthalmitis, choroidal detachment or incision related retinal hole occurred. The intraoperative and postoperative parameters in the preoperative retinal photocoagulation group were better than the preoperative non-photocoagulation group, but the difference was not significant (P>0.05). Conclusions: Minimally invasive vitrectomy is fully qualified for the management of severe PDR, with maximized benefits. (Chin J Ophthalmol, 2021, 57:440-446). 目的: 探讨最小量化玻璃体切除术治疗严重增生性糖尿病视网膜病变(PDR)的疗效及术前视网膜激光光凝对预后的影响。 方法: 系列病例研究及队列研究。将2017年1月1日至2019年3月30日就诊于天津医科大学眼科医院的48例(53只眼)严重PDR患者纳入本研究。其中男性28例,女性20例;年龄53.5(40.0,59.0)岁。采取“最小量化”玻璃体切除术理念进行手术:所有患者术前3 d玻璃体腔注射康柏西普;以27G+玻璃体切除系统完成标准三通道玻璃体切除术;术中不追求彻底清除增生机化膜,以解除牵拉为主;灵活应用27G+玻璃体切割头来完成各种手术步骤,减少器械进出眼内次数;术中完成主要区域视网膜激光光凝。术后主要观察指标为最佳矫正视力(BCVA)和视网膜复位率,次要观察指标为术中和术后并发症情况,并按术前是否进行视网膜激光光凝分为光凝组和无光凝组分别进行分析。采用t检验、秩和检验及χ²检验进行统计学分析。 结果: 所有患者玻璃体腔注射康柏西普后均无严重不良反应发生。术前和术后1周、1个月、3个月、6个月,BCVA分别为1.90(1.30,2.30)、1.00(0.70,1.90)、0.80(0.50,1.30)、0.70(0.40,1.20)、0.70(0.40,1.20)。与术前相比,术后BCVA显著提高,差异有统计学意义(χ²=125.11,P<0.01)。随着随访时间的延长,视功能逐步改善。术后首次和末次随访视网膜复位率分别为92.5%(50/53)和96.2%(51/53)。2只眼术后发生持续1周及以上的异常眼压;5只眼复发玻璃体积血(9.4%);4只眼(7.5%)发生视网膜脱离;未发生术后眼内炎、脉络膜脱离或切口相关的视网膜裂孔。光凝组术中(手术时间、硅油填充率、视网膜切开术率)及术后(术后BCVA、首次随访复位率、末次随访复位率、再手术率)各项参数与无光凝组相比,差异无统计学意义(P>0.05),但光凝组具有更好的趋势。 结论: 最小量化玻璃体切除术能够使严重PDR患者术后获得较好的视功能,以较小的创伤获取较大的收益;术前视网膜激光光凝可能有助于术后视力恢复。(中华眼科杂志,2021,57:440-446).
引用
- Zheng CZ, Ren XJ, Ke YF, et al. [Minimally invasive vitrectomy for the treatment of severe proliferative diabetic retinopathy]. Zhonghua Yan Ke Za Zhi. 2021. PMID: 34098693. doi:10.3760/cma.j.cn112142-20200812-00538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。